{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-25-000029","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.365097+00:00","generated_at":"2026-05-24T01:54:54.281819+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Keros announces positive Phase 1 results for KER-065; plans Phase 2 in DMD in Q1 2026","bullets":["KER-065 generally well-tolerated; no serious adverse events or dose-limiting toxicities reported.","Evidence of activin inhibition: increases in BSAP, adiponectin, and bone density; decreases in CTX, leptin, and fat mass.","Body composition changes included increased muscle mass and reduced fat mass consistent with activin inhibition.","Company expects to initiate Phase 2 trial in Duchenne muscular dystrophy in Q1 2026 after regulatory engagement.","Phase 1 data cut-off Feb 6, 2025; multiple ascending dose period through Day 85 completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-25-000029","json":"https://secwatch.observer/filing/0001664710-25-000029.json","markdown":"https://secwatch.observer/filing/0001664710-25-000029.md","text":"https://secwatch.observer/filing/0001664710-25-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000029/0001664710-25-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000029/kros-20250331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:54:54.281819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}